Meningioma Market to Exhibit Moderate Growth Rate till 2030, Investigates DelveInsight | Key Companies – Takeda, Clarity Pharma, Actuate Therapeutics, and Others

 Breaking News
  • No posts were found

Meningioma Market to Exhibit Moderate Growth Rate till 2030, Investigates DelveInsight | Key Companies – Takeda, Clarity Pharma, Actuate Therapeutics, and Others

December 13
18:17 2021
Meningioma Market to Exhibit Moderate Growth Rate till 2030, Investigates DelveInsight | Key Companies - Takeda, Clarity Pharma, Actuate Therapeutics, and Others
Delveinsight Business Research LLP
DelveInsight’s “Meningioma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Meningioma Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Meningioma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Meningioma Market

Meningioma: An Overview

Meningiomas are the most common benign intracranial tumor. They originate from arachnoid cap cells, which are cells within the thin, spiderweb-like membrane that covers the brain and spinal cord. The arachnoid is one of three protective layers, collectively known as the meninges, which surround the brain and the spinal cord. 

Meningioma Market Key Facts

  • Data from the Central Brain Tumor Registry of the United States (CBTRUS) demonstrates a more than twofold higher incidence among females [age-adjusted incidence rate (per 100,000 person-years) of 8.36 and 3.61 for females and males, respectively]. The female: male ratio of approximately 2:1 may be inverted for rare pre-pubertal meningiomas.

  • Atypical and malignant meningiomas comprise a small fraction of the total (~5%) and have a slight male predominance. Reported rates for Black Non-Hispanics are slightly higher (6.67) than for White Non-Hispanic and Hispanics (5.90 and 5.94, respectively). 

Meningioma Market

Meningioma market size is expected to increase during the study period owing to the increasing incident population in the 7MM, extensive research and development activities of pharmaceutical companies, and the expected launch of approved therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Meningioma market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Meningioma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Meningioma Epidemiology

The epidemiology section covers insights about the historical and current Meningioma patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Meningioma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Meningioma market or expected to get launched in the market during the study period. The analysis covers the Meningioma market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Meningioma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Meningioma Therapeutics Analysis

Companies all over the globe are persistently working towards the development of new treatment therapies for Meningioma. The launch of the emerging therapies is expected to improve the treatment scenario in the coming years. 

Some of the key Companies in the Meningioma market include:

  • Takeda

  • Clarity Pharmaceuticals

  • Actuate Therapeutics 

And many others.

Meningioma Therapies covered in the report include

  • Brigatinib


  • 9-ING-41

  • Sunitinib

  • Bevacizumab

And many others.

Request for Sample @

Table of Content

1. Key Insights

2. Executive Summary 

3. Meningioma Competitive Intelligence Analysis

4. Meningioma Market Overview at a Glance

5. Meningioma Disease Background and Overview

6. Meningioma Patient Journey

7. Meningioma Epidemiology and Patient Population

8. Meningioma Treatment Algorithm, Current Treatment, and Medical Practices

9. Meningioma Unmet Needs

10. Key Endpoints of Meningioma Treatment

11. Meningioma Marketed Products

12. Meningioma Emerging Therapies

13. Meningioma Seven Major Market Analysis

14. Attribute Analysis

15. Meningioma Market Outlook (7 major markets)

16. Meningioma Access and Reimbursement Overview

17. KOL Views on the Meningioma Market.

18. Meningioma Market Drivers

19. Meningioma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight

Bevacizumab Biosimilars

DelveInsight’s, “Bevacizumab Biosimilar Insight, 2020,” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

Related Articles


January 2022